Hanmi’s Once Weekly Efpeglenatide Bests Liraglutide In Phase II
This article was originally published in PharmAsia News
In its ongoing push to seek a global partner for its diabetes therapies, South Korea's major pharma firm Hanmi has presented the results of Phase IIb study for a once weekly form of its diabetes therapy efpeglenatide, which showed benefits over Novo Nordisk’s rival therapy Victoza.
You may also be interested in...
After initial rejection and resubmission, FDA approves ultra-long-acting insulin Tresiba, and also Ryzodeg, which combines Tresiba and the company’s meal-time insulin NovoLog.
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.